索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]阚通,陈亮,秦永文.他汀类药物在心力衰竭中的应用[J].国际心血管病杂志,2015,06:388-390.
点击复制

他汀类药物在心力衰竭中的应用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2015年06期
页码:
388-390
栏目:
综述
出版日期:
2015-11-25

文章信息/Info

Title:
-
作者:
阚通; 陈亮; 秦永文
200433 上海,第二军医大学附属长海医院心血管内科
Author(s):
-
关键词:
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂; 炎症反应; 心力衰竭; 舒张功能
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2015.06.006
文献标识码:
-
摘要:
他汀类药物应用于心力衰竭患者,具有改善左心室舒张功能、抑制心室重构和改善心肌收缩力的作用。该文结合他汀类药物的作用机制,总结他汀类药物在心力衰竭治疗中的应用进展。
Abstract:
-

参考文献/References

[1] Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and by invited experts)[J]. Eur J Cardiovasc Prev Rehabil, 2007,14 Suppl 2:S1-S113.
[2] Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators[J]. N Engl J Med, 1996,335(14):1001-1009.
[3] Tousoulis D, Oikonomou E, Siasos G, et al. Predictive value of biomarkers in patients with heart failure[J]. Curr Med Chem, 2012,19(16):2534-2547.
[4] Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure[J]. J Am Coll Cardiol, 2006,47(2):332-337.
[5] Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure[J]. J Card Fail, 2008,14(2):140-144.
[6] Tousoulis D, Antoniades C, Katsi V, et al. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level[J]. Int J Cardiol, 2006,109(1):48-52.
[7] Oikonomou E, Tousoulis D, Siasos G, et al. The role of inflammation in heart failure: new therapeutic approaches[J]. Hellenic J Cardiol, 2011,52(1):30-40.
[8] Wang Y, Zhang MX, Meng X, et al. Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells[J]. Am J Physiol Heart Circ Physiol, 2011,300(5):H1743-H1752.
[9] Aviram M, Rosenblat M, Bisgaier CL, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation[J]. Atherosclerosis, 1998,138(2):271-280.
[10] Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target[J]. Arterioscler Thromb Vasc Biol, 2005,25(5):923-931.
[11] Wu K, Tian S, Zhou H, et al. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation[J]. Biochem Pharmacol, 2013,85(12):1753-1760.
[12] Briasoulis A, Tousoulis D, Androulakis ES, et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches[J]. Recent Pat Cardiovasc Drug Discov, 2012,7(1):21-32.
[13] Takayama N, Kai H, Kudo H, et al. Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras-ERK pathways[J]. Hypertens Res, 2011,34(3):341-347.
[14] Choi EY, Chang W, Lim S, et al. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh[J]. Eur J Pharmacol, 2010,627(1-3):56-62.
[15] Mannheim D, Herrmann J, Bonetti PO, et al. Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect[J]. Atherosclerosis, 2011,216(2):283-291.
[16] Chang SA, Kim YJ, Lee HW, et al. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy[J]. Hypertension, 2009,54(3):591-597.
[17] Xu Z, Okamoto H, Akino M, et al. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin Ⅱ-induced hypertensive mice[J]. J Cardiovasc Pharmacol, 2008,51(1):62-70.
[18] Zheng X, Hu SJ. Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart[J]. Acta Pharmacol Sin, 2005,26(6):696-704.
[19] Talini E, Di BV, Bianchi C, et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study[J]. Atherosclerosis, 2008,197(1):346-354.
[20] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2012,14(8):803-869.
[21] Jassal DS, Bhagirath KM, Karlstedt E, et al. Evaluating the effectiveness of rosuvastatin in preventing the progression of diastolic dysfunction in aortic stenosis: A substudy of the aortic stenosis progression observation measuring effects of rosuvastatin(ASTRONOMER)study[J]. Cardiovasc Ultrasound, 2011,9(1):5.
[22] Bauersachs J, Stork S, Kung M, et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study[J]. Eur J Clin Invest, 2007,37(11):852-859.
[23] Hong YJ, Jeong MH, Hyun DW, et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction[J]. Am J Cardiol, 2005,95(5):619-622.
[24] Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study[J]. Am Heart J, 2007,153(6):1055.e1-e8.
[25] Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008,372(9645):1231-1239.
[26] Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure[J]. N Engl J Med, 2007,357(22):2248-2261
[27] Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure[J]. Atherosclerosis, 2013,227(2):367-372.

备注/Memo

备注/Memo:
作者单位:200433 上海,第二军医大学附属长海医院心血管内科 通信作者:秦永文,Email:chqinyw@163.com
更新日期/Last Update: 2015-12-20